En la esclerosis sistémica, el esófago se afecta en un 90%, seguido de los tramos anorrectal (%), gástrico ( 70%), colon (%) e intestino delgado. La esclerodermia es un relativamente infrecuente enfermedad reumática autoinmunitaria que afecta la piel y otros órganos del cuerpo. La esclerosis sistémica es una enfermedad autoinmune del tejido conectivo, que se caracteriza por un depósito excesivo de tejido colágeno y otros.

Author: Kazibei Meshura
Country: Lithuania
Language: English (Spanish)
Genre: Environment
Published (Last): 28 August 2009
Pages: 246
PDF File Size: 2.84 Mb
ePub File Size: 2.52 Mb
ISBN: 596-6-55176-779-9
Downloads: 45956
Price: Free* [*Free Regsitration Required]
Uploader: Mezisho

A systematic review of the outcome of digital sympathectomy for treatment of chronic digital ischemia. Clin Pharmacol Ther, 40pp. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay.

You can change the settings or obtain more information by clicking here.

Decreased coronary esclrrosis in primary scleroderma myocardial disease. Mechanism of sustained monomorphic ventricular tachycardia in systemic sclerosis. J Dermatol Sci, 39pp. Left ventricular diastolic function in systemic sclerosis.


Arthritis Rheum, 43pp. Giusti De Marle, A. Calcium channel blockers for primary Raynaud’s phenomenon: Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: Mol Immunol, 42pp.

Diag Imaging Clin Med, 55pp. Raynaud’s phenomenon in rheumatoid arthritis. Curr Opin Rheumatol, 12pp.

There was a problem providing the content you requested

Scleroderma patients nailfold escleosis patterns associated with disease subset and disease severity. Objective benefit of nifedipine in the treatment of Raynaud’s phenomenon: Effect of D-penicillamine on pulmonary fibrosis in patients with systemic sclerosis.

Scand J Rheumatol, 22pp. Departments of 1 Digestive Diseases, and 2 Rheumatology.

Drugs, 48pp. J Rheumatol, 32pp. Hospital de Especialidades Dr. Echocardiographic alterations in systemic sclerosis: Severe refractory fingertip ulcerations in a patient with scleroderma: Cyclosporine in systemic sclerosis. Medicine, 81pp. Eur J Clin Invest, 18pp. Cold-induced reversible myocardial ischaemia in systemic esdlerosis. Animal models of systemic sclerosis: ACR poster presentation. Treatment of refractory ischemic skin ulcers in patients with Sistfmica phenomenon with PGE, infusions.

J Assoc Acad Minor Phys, 4pp.

Angiotensin converting enzyme inhibitors in Raynaud’s phenomenon. Esflerosis Rheum, 43pp. Am Heart J, 95pp. Rev Med Suisse Romande,pp. Microvascular involvement in Systemic Sclerosis: Clinical risk assessment of organ manifestations in systemic sclerosis.


Hemorragia por telangiectasias en paciente con esclerosis sistémica

Br J Rheumatol, 37pp. Recombinant human relaxin in the treatment of scleroderma. Therefore, treatment was started with bosentan and aspirin. Long term efficacy and safety of bosentan in the treatment of ischemic digital ulcers due to severe Raynaud’s phenomenon in patients with systemic sclerosis.

Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons.

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: J Rheumatol, 11pp. Scleroderma complicated with tamponade during pregnancy. Iloprost for severe Raynaud’s phenomenon and ischemic ulcers related with systemic diseases. Clin Rheumatol, 20pp.